European Funding for MedTech Companies: Grants, Strategy and the CE Marking Pathway

Why MedTech is one of the strongest sectors for European grants

MedTech is consistently overrepresented in successful European grant applications, particularly in Eurostars and Horizon Europe. Several structural reasons explain this: MedTech R&D is inherently long-cycle and capital-intensive, which aligns with grant programme logic. Clinical validation - a prerequisite for CE marking - is clearly grant-eligible as it involves genuine technical and scientific uncertainty. And the sector's safety-critical nature means that detailed, evidence-based R&D documentation (a requirement for grant applications) is already standard practice.

For MedTech founders, grants are a strategic instrument: they fund the clinical evidence generation that enables regulatory clearance, which in turn unlocks enterprise sales and follow-on investment.

What MedTech R&D is eligible for European grants?

The following MedTech activities are clearly grant-eligible:

• Medical device development (Class I-III): R&D from concept through prototype to clinical-grade device, including material science, miniaturisation, and biocompatibility research.
• Clinical validation studies: Preclinical studies, feasibility trials, and clinical investigations supporting CE marking and FDA 510(k) submissions.
• AI/ML for clinical decision support: Development of diagnostic algorithms, imaging AI, and predictive models for clinical outcomes - particularly strong in Eurostars evaluations.
• Digital health platform R&D: Development of novel software as a medical device (SaMD), remote patient monitoring architectures, and connected health data pipelines.
• Surgical robotics and instrumentation: Mechanical design, haptics, computer vision, and motion planning research for surgical and procedural tools.
• In-vitro diagnostics (IVD): Assay development, biomarker discovery, point-of-care testing platforms, and multiplex detection technologies.

Eurostars: the primary route for MedTech SMEs

Eurostars is consistently the highest-performing programme for MedTech SMEs in terms of success rate and accessibility. Medical devices, digital diagnostics, and clinical AI companies are among the programme's most competitive applicants. The bilateral R&D structure is natural for MedTech - many clinical validation strategies already require collaboration with European clinical research organisations or partner device companies.

A MedTech company developing a Class IIa device in Germany, for example, might partner with a Dutch CRO or a Belgian medical university-affiliated SME to conduct the clinical feasibility study - and fund the entire collaboration through Eurostars. The grant covers 35-60% of project costs; the clinical evidence generated supports CE marking under MDR.

Horizon Europe Cluster 1: the large-budget clinical research route

Horizon Europe's Cluster 1 (Health) is the EU's primary mechanism for large-scale clinical and biomedical research. Calls in this cluster fund cancer research, rare diseases, infectious diseases, digital health and cardiovascular conditions - typically with multi-partner consortia and 4-6 year project durations. Individual company budgets within Horizon consortia can reach €2-3M.

Horizon Cluster 1 is better suited to established MedTech companies or those with strong clinical partnership networks. The longer timeline (8-12 months from call to award) and complex consortium requirements make it less accessible for early-stage companies.

Aligning grant strategy with the CE marking pathway

The most sophisticated MedTech funding strategies align grant scope precisely with CE marking requirements. Under EU MDR (Medical Device Regulation), clinical evidence must demonstrate safety and performance throughout the device's intended use. The evidence generation process - preclinical studies, clinical investigations, PMCF - maps directly to grant-eligible R&D activities.

A well-structured Eurostars application for a Class IIb device might fund the following: technical file preparation, preclinical validation, clinical feasibility study, and software validation - all as defined work packages. The grant funds the regulatory pathway; CE marking enables market entry; market entry enables Series B. This is the MedTech funding stack at its most efficient.

EIC Accelerator for breakthrough MedTech

For MedTech companies with genuinely breakthrough technology - new diagnostic modalities, novel therapeutic approaches, or disruptive platform technologies - the EIC Accelerator is the highest-value European funding instrument. The combination of €2.5M grant and optional €15M equity investment is specifically designed for the capital-intensive commercialisation phase that defines MedTech scale-up.

MedTech companies that have successfully navigated EIC evaluation typically have: CE marking achieved or imminent, first clinical installations demonstrating real-world performance, and a clear path to €50M+ market within 5 years. The EIC jury process demands both clinical credibility and commercial ambition.